Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
10(63%)
Results Posted
75%(3 trials)

Phase Distribution

Ph phase_3
2
13%
Ph phase_1
1
6%
Ph phase_2
3
19%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

10

trials recruiting

Total Trials

16

all time

Status Distribution
Active(10)
Completed(4)
Other(2)

Detailed Status

Recruiting7
Completed4
Active, not recruiting3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
16
Active
10
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 23 (50.0%)
Phase 32 (33.3%)

Trials by Status

completed425%
active_not_recruiting319%
recruiting744%
unknown213%

Recent Activity

10 active trials
Showing 5 of 16
recruitingphase_3

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

NCT07128550
recruitingphase_2

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

NCT07454837
recruiting

Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D

NCT07491848
unknown

Expanded Access for Bulevirtide

NCT06780579
completedphase_1

Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function

NCT05765344
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT07128550Phase 3

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

Recruiting
NCT07454837Phase 2

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

Recruiting
NCT07491848

Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D

Recruiting
NCT06780579

Expanded Access for Bulevirtide

Unknown
NCT05765344Phase 1

Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function

Completed
NCT07142811Phase 2

A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection

Active Not Recruiting
NCT06504485

Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment

Recruiting
NCT05718700

Study of Bulevirtide in Participants With Chronic Hepatitis D Infection

Active Not Recruiting
NCT04863703

Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)

Active Not Recruiting
NCT03852719Phase 3

Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD)

Completed
NCT06122285

Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)

Recruiting
NCT03852433Phase 2

Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

Completed
NCT06397859

Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis

Recruiting
NCT06051045

Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients

Recruiting
NCT05962307

Efficacy and Safety of Bulevirtide (BLV) Therapy in HDV Chronic Hepatitis (CHD) in Italy

Completed
NCT05928000

HEllenic Multicenter ReAl-life CLInical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV

Unknown

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16